Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LXE408
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Within the scope of the agreement, Novartis is responsible for completing Phase I clinical trials and DNDi will lead Phase II and Phase III development in India.
Product Name : LXE408
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 25, 2020
Lead Product(s) : LXE408
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement